A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)
The purpose of this phase III study is to test the effectiveness of inclisiran sodium 300 mg in addition to well-tolerated high-intensity statin therapy in participants with established cardiovascular disease in reducing cardiovascular events including death, non-fatal MI, and non-fatal stroke.
DiagnosisElevated LDL > 70mg/dL; Established cardiovascular disease defined as previous myocardial infarction, stroke, or symptomatic cardiovascular disease
Patient needs to be on a stable (4 weeks or more) of high intensity statin at Screening Patients with the ailments below will not be eligible
- Recent MI, stroke, revascularization procedure
- Severe Heart Failure, Class III or IV
- Acute Liver Disease
- Active Cancer
Inclisiran versus placebo
For more information, visit the U.S. National Library of Medicine clinical trial database.